Raras
Buscar doenças, sintomas, genes...
NÃO RARA NA EUROPA: Doença de Parkinson
ORPHA:319705CID-10 · G20DOENÇA RARA

Doença degenerativa progressiva do sistema nervoso central caracterizada pela perda de neurônios produtores de dopamina na substância negra e pela presença de corpos de Lewy na substância negra e no locus coeruleus. Os sinais e sintomas incluem tremor que é mais pronunciado durante o repouso, rigidez muscular, lentidão dos movimentos voluntários, tendência a cair para trás e uma expressão facial semelhante a uma máscara.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença degenerativa progressiva do sistema nervoso central caracterizada pela perda de neurônios produtores de dopamina na substância negra e pela presença de corpos de Lewy na substância negra e no locus coeruleus. Os sinais e sintomas incluem tremor que é mais pronunciado durante o repouso, rigidez muscular, lentidão dos movimentos voluntários, tendência a cair para trás e uma expressão facial semelhante a uma máscara.

Publicações científicas
2 artigos
Último publicado: 2014 Nov-Dec
Medicamentos
5 registrados
CARBIDOPA, AMANTADINE HYDROCHLORIDE, LEVODOPA

Tem tratamento?

5 medicamentos registrados
Ver detalhes, fases e interações →
CARBIDOPAAMANTADINE HYDROCHLORIDELEVODOPAOPICAPONEROPINIROLE HYDROCHLORIDE
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G20
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
43 sintomas
💪
Músculos
12 sintomas
🫃
Digestivo
7 sintomas
🦴
Ossos e articulações
5 sintomas
👁️
Olhos
5 sintomas
😀
Face
3 sintomas

+ 83 sintomas em outras categorias

Características mais comuns

Rigidez em roda denteada
Incontinência intestinal
Hiperreflexia em membros superiores
Reflexo patelar hiperativo
Fraqueza muscular generalizada
Hiperreflexia do membro inferior
165sintomas
Sem dados (165)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 165 características clínicas mais associadas, ordenadas por frequência.

Rigidez em roda denteadaCogwheel rigidity
Incontinência intestinalBowel incontinence
Hiperreflexia em membros superioresHyperreflexia in upper limbs
Reflexo patelar hiperativoHyperactive patellar reflex
Fraqueza muscular generalizadaGeneralized muscle weakness

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Total histórico2PubMed
Últimos 10 anos81publicações
Pico202514 papers
Linha do tempo
20202015Hoje · 2026📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

27 genes identificados com associação a esta condição.

DNAJC6AuxilinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May act as a protein phosphatase and/or a lipid phosphatase. Co-chaperone that recruits HSPA8/HSC70 to clathrin-coated vesicles (CCVs) and promotes the ATP-dependent dissociation of clathrin from CCVs and participates in clathrin-mediated endocytosis of synaptic vesicles and their recycling and also in intracellular trafficking (PubMed:18489706). Firstly, binds tightly to the clathrin cages, at a ratio of one DNAJC6 per clathrin triskelion. The HSPA8:ATP complex then binds to the clathrin-auxili

LOCALIZAÇÃO

Cytoplasmic vesicle, clathrin-coated vesicle

VIAS BIOLÓGICAS (3)
Clathrin-mediated endocytosisLysosome Vesicle BiogenesisGolgi Associated Vesicle Biogenesis
MECANISMO DE DOENÇA

Parkinson disease 19A, juvenile-onset

A juvenile form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK19A is characterized by onset of parkinsonian symptoms in the first or second decade of life. Some patients may have additional neurologic features, including intellectual disability and seizures.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
80.0 TPM
Brain Frontal Cortex BA9
69.8 TPM
Brain Spinal cord cervical c-1
62.9 TPM
Cerebelo
51.3 TPM
Hipotálamo
49.0 TPM
OUTRAS DOENÇAS (3)
juvenile onset Parkinson disease 19Aatypical juvenile parkinsonismyoung-onset Parkinson disease
HGNC:15469UniProt:O75061
ATXN8OSPutative protein ATXN8OSCandidate gene tested inDesconhecido
LOCALIZAÇÃO

Cytoplasm

OUTRAS DOENÇAS (2)
spinocerebellar ataxia type 8late-onset Parkinson disease
HGNC:10561UniProt:P0DMR3
ATXN2Ataxin-2Candidate gene tested inAltamente restrito
FUNÇÃO

Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Spinocerebellar ataxia 2

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA2 is characterized by hyporeflexia, myoclonus and action tremor and dopamine-responsive parkinsonism. In some patients, SCA2 presents as pure familial parkinsonism without cerebellar signs.

OUTRAS DOENÇAS (3)
spinocerebellar ataxia type 2amyotrophic lateral sclerosislate-onset Parkinson disease
HGNC:10555UniProt:Q99700
MAPTMicrotubule-associated protein tauCandidate gene tested inTolerante
FUNÇÃO

Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity (PubMed:21985311). The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both (PubMed:21985311, PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isofo

LOCALIZAÇÃO

Cytoplasm, cytosolCell membraneCytoplasm, cytoskeletonCell projection, axonCell projection, dendriteSecreted

VIAS BIOLÓGICAS (1)
Caspase-mediated cleavage of cytoskeletal proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
223.0 TPM
Cérebro - Hemisfério cerebelar
218.9 TPM
Córtex cerebral
161.2 TPM
Brain Frontal Cortex BA9
156.7 TPM
Brain Anterior cingulate cortex BA24
104.1 TPM
OUTRAS DOENÇAS (10)
Pick diseaseprogressive supranuclear palsy-parkinsonism syndromesemantic dementiasupranuclear palsy, progressive, 1
HGNC:6893UniProt:P10636
ADH1CAlcohol dehydrogenase 1CCandidate gene tested inTolerante
FUNÇÃO

Alcohol dehydrogenase. Exhibits high activity for ethanol oxidation and plays a major role in ethanol catabolism

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
RA biosynthesis pathwayEthanol oxidation
OUTRAS DOENÇAS (2)
alcohol dependencelate-onset Parkinson disease
HGNC:HGNC:251UniProt:P00326
TBPTATA-box-binding proteinCandidate gene tested inAltamente restrito
FUNÇÃO

The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:2194289, PubMed:2363050, PubMed:2374612, PubMed:27193682, PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2,

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 17

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA17 is an autosomal dominant cerebellar ataxia (ADCA) characterized by widespread cerebral and cerebellar atrophy, dementia and extrapyramidal signs. The molecular defect in SCA17 is the expansion of a CAG repeat in the coding region of TBP. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
52.5 TPM
Linfócitos
28.7 TPM
Fallopian Tube
26.9 TPM
Útero
24.9 TPM
Ovário
24.9 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia type 17late-onset Parkinson disease
HGNC:11588UniProt:P20226
ATXN3Ataxin-3Candidate gene tested inTolerante
FUNÇÃO

Deubiquitinating enzyme involved in protein homeostasis maintenance, transcription, cytoskeleton regulation, myogenesis and degradation of misfolded chaperone substrates (PubMed:12297501, PubMed:16118278, PubMed:17696782, PubMed:23625928, PubMed:28445460, PubMed:33157014). Binds long polyubiquitin chains and trims them, while it has weak or no activity against chains of 4 or less ubiquitins (PubMed:17696782). Involved in degradation of misfolded chaperone substrates via its interaction with STUB

LOCALIZAÇÃO

Nucleus matrixNucleusLysosome membrane

VIAS BIOLÓGICAS (2)
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genesJosephin domain DUBs
MECANISMO DE DOENÇA

Spinocerebellar ataxia 3

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA3 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. The molecular defect in SCA3 is the a CAG repeat expansion in ATX3 coding region. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.

OUTRAS DOENÇAS (5)
Machado-Joseph diseaseMachado-Joseph disease type 3Machado-Joseph disease type 2Machado-Joseph disease type 1
HGNC:7106UniProt:P54252
PODXLPodocalyxinCandidate gene tested inRestrito
FUNÇÃO

Involved in the regulation of both adhesion and cell morphology and cancer progression. Functions as an anti-adhesive molecule that maintains an open filtration pathway between neighboring foot processes in the podocyte by charge repulsion. Acts as a pro-adhesive molecule, enhancing the adherence of cells to immobilized ligands, increasing the rate of migration and cell-cell contacts in an integrin-dependent manner. Induces the formation of apical actin-dependent microvilli. Involved in the form

LOCALIZAÇÃO

Apical cell membraneCell projection, lamellipodiumCell projection, filopodiumCell projection, ruffleCell projection, microvillusMembrane raftMembrane

VIAS BIOLÓGICAS (1)
Cytosolic sulfonation of small molecules
EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Córtex
161.5 TPM
Pulmão
133.5 TPM
Tireoide
89.0 TPM
Útero
85.2 TPM
Fallopian Tube
74.8 TPM
OUTRAS DOENÇAS (2)
atypical juvenile parkinsonismyoung-onset Parkinson disease
HGNC:9171UniProt:O00592
HTRA2Serine protease HTRA2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Serine protease that shows proteolytic activity against a non-specific substrate beta-casein (PubMed:10873535). Promotes apoptosis by either relieving the inhibition of BIRC proteins on caspases, leading to an increase in caspase activity; or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism (PubMed:15200957). Cleaves BIRC6 and relieves its inhibition on CASP3, CASP7 and CASP9, but it is also prone to inhibition by BIRC6 (PubMed:36758104, PubM

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrion membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (2)
Mitochondrial unfolded protein response (UPRmt)Mitochondrial protein degradation
MECANISMO DE DOENÇA

3-methylglutaconic aciduria 8

An autosomal recessive inborn error of metabolism resulting in early death. Clinical features include extreme hypertonia observed at birth, alternating with hypotonia, subsequent appearance of extrapyramidal symptoms, lack of psychomotor development, microcephaly, and intractable seizures. Patients show lactic acidemia, 3-methylglutaconic aciduria, intermittent neutropenia, and progressive brain atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
62.3 TPM
Útero
44.3 TPM
Cervix Ectocervix
44.1 TPM
Ovário
44.0 TPM
Cervix Endocervix
43.3 TPM
OUTRAS DOENÇAS (3)
3-methylglutaconic aciduria type 8young-onset Parkinson diseaseParkinson disease 13, autosomal dominant, susceptibility to
HGNC:14348UniProt:O43464
UCHL1Ubiquitin carboxyl-terminal hydrolase isozyme L1Candidate gene tested inAltamente restrito
FUNÇÃO

Deubiquitinase that plays a role in the regulation of several processes such as maintenance of synaptic function, cardiac function, inflammatory response or osteoclastogenesis (PubMed:22212137, PubMed:23359680). Abrogates the ubiquitination of multiple proteins including WWTR1/TAZ, EGFR, HIF1A and beta-site amyloid precursor protein cleaving enzyme 1/BACE1 (PubMed:22212137, PubMed:25615526). In addition, recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin to maintain

LOCALIZAÇÃO

CytoplasmEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
UCH proteinases
MECANISMO DE DOENÇA

Parkinson disease 5

A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
1197.5 TPM
Córtex cerebral
948.1 TPM
Hipotálamo
894.5 TPM
Brain Anterior cingulate cortex BA24
700.8 TPM
Brain Nucleus accumbens basal ganglia
687.1 TPM
OUTRAS DOENÇAS (4)
early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndromespastic paraplegia 79A, autosomal dominant, with ataxiayoung-onset Parkinson diseaseParkinson disease 5, autosomal dominant, susceptibility to
HGNC:12513UniProt:P09936
GIGYF2GRB10-interacting GYF protein 2Candidate gene tested inAltamente restrito
FUNÇÃO

Key component of the 4EHP-GYF2 complex, a multiprotein complex that acts as a repressor of translation initiation (PubMed:22751931, PubMed:31439631, PubMed:35878012). In the 4EHP-GYF2 complex, acts as a factor that bridges EIF4E2 to ZFP36/TTP, linking translation repression with mRNA decay (PubMed:31439631). Also recruits and bridges the association of the 4EHP complex with the decapping effector protein DDX6, which is required for the ZFP36/TTP-mediated down-regulation of AU-rich mRNA (PubMed:3

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Parkinson disease 11

A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
46.4 TPM
Fibroblastos
24.6 TPM
Linfócitos
24.1 TPM
Útero
23.5 TPM
Nervo tibial
22.4 TPM
OUTRAS DOENÇAS (2)
late-onset Parkinson diseaseParkinson disease 11, autosomal dominant, susceptibility to
HGNC:11960UniProt:Q6Y7W6
EIF4G1Eukaryotic translation initiation factor 4 gamma 1Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome (PubMed:29987188). Exists in two complexes, either with EIF1 or with EIF4E (mutually exclusive) (PubMed:29987188). Together with EIF1, is required for leaky scanning, in particular for avoiding cap-proximal start codon (PubMed:29987188). Together with EIF4E, antagonizes the scanning promoted by EIF1-EIF4G1

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, Stress granule

VIAS BIOLÓGICAS (10)
ISG15 antiviral mechanismDengue Virus Genome Translation and ReplicationmTORC1-mediated signallingDeadenylation of mRNAZ-decay: degradation of maternal mRNAs by zygotically expressed factors
MECANISMO DE DOENÇA

Parkinson disease 18

An autosomal dominant, late-onset form of Parkinson disease. Parkinson disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
251.4 TPM
Músculo esquelético
232.0 TPM
Skin Sun Exposed Lower leg
189.9 TPM
Esôfago - Mucosa
188.7 TPM
Skin Not Sun Exposed Suprapubic
179.8 TPM
OUTRAS DOENÇAS (2)
late-onset Parkinson diseaseParkinson disease 18, autosomal dominant, susceptibility to
HGNC:3296UniProt:Q04637
GBA1Lysosomal acid glucosylceramidaseCandidate gene tested inTolerante
FUNÇÃO

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:15916907, PubMed:24211208, PubMed:32144204, PubMed:39395789, PubMed:9201993). Plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates in the PKC-activ

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Gaucher disease

An autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD is a multisystem disease historically divided into three main subtypes on the basis of the presence of neurologic involvement, age at onset and progression rate: type 1 is the non-neuropathic form, type 2 is the acute neuropathic form with early onset and rapid neurologic deterioration, type 3 is the chronic neuropathic form with slow progression of neurologic features. GD shows a marked phenotypic diversity ranging from adult asymptomatic forms, at the mild end, to perinatal lethal forms at the severe end of the disease spectrum. Formal diagnosis of Gaucher disease is based on the measurement of glucocerebrosidase levels in circulating leukocytes and molecular genetic analysis.

OUTRAS DOENÇAS (7)
Gaucher disease type IIGaucher disease perinatal lethalGaucher disease-ophthalmoplegia-cardiovascular calcification syndromeGaucher disease type I
HGNC:4177UniProt:P04062
LRRK2Leucine-rich repeat serine/threonine-protein kinase 2Candidate gene tested inTolerante
FUNÇÃO

Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:21850687, PubMed:22012985, PubMed:23395371, PubMed:24687852, PubMed:25201882, PubMed:26014385, PubMed:26824392, PubMed:27830463, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421). Is a key regulator of RAB GTPases b

LOCALIZAÇÃO

Cytoplasmic vesiclePerikaryonGolgi apparatus membraneCell projection, axonCell projection, dendriteEndoplasmic reticulum membraneCytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneEndosomeLysosomeMitochondrion outer membraneCytoplasm, cytoskeletonCytoplasmic vesicle, phagosome

VIAS BIOLÓGICAS (1)
PTK6 promotes HIF1A stabilization
MECANISMO DE DOENÇA

Parkinson disease 8

A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
29.7 TPM
Sangue
21.6 TPM
Nervo tibial
17.4 TPM
Aorta
12.6 TPM
Artéria tibial
11.9 TPM
OUTRAS DOENÇAS (3)
late-onset Parkinson diseaseyoung-onset Parkinson diseaseautosomal dominant Parkinson disease 8
HGNC:18618UniProt:Q5S007
VPS35Vacuolar protein sorting-associated protein 35Candidate gene tested inAltamente restrito
FUNÇÃO

Acts as a component of the retromer cargo-selective complex (CSC). The CSC is believed to be the core functional component of retromer or respective retromer complex variants acting to prevent missorting of selected transmembrane cargo proteins into the lysosomal degradation pathway. The recruitment of the CSC to the endosomal membrane involves RAB7A and SNX3. The CSC seems to associate with the cytoplasmic domain of cargo proteins predominantly via VPS35; however, these interactions seem to be

LOCALIZAÇÃO

CytoplasmMembraneEndosomeEarly endosomeLate endosome

VIAS BIOLÓGICAS (1)
WNT ligand biogenesis and trafficking
MECANISMO DE DOENÇA

Parkinson disease 17

An autosomal dominant, adult-onset form of Parkinson disease. Parkinson disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
45.5 TPM
Linfócitos
39.7 TPM
Artéria tibial
38.0 TPM
Testículo
36.7 TPM
Bladder
35.9 TPM
OUTRAS DOENÇAS (2)
late-onset Parkinson diseaseParkinson disease 17
HGNC:13487UniProt:Q96QK1
DNAJC13DnaJ homolog subfamily C member 13Candidate gene tested inAltamente restrito
FUNÇÃO

Involved in membrane trafficking through early endosomes, such as the early endosome to recycling endosome transport implicated in the recycling of transferrin and the early endosome to late endosome transport implicated in degradation of EGF and EGFR (PubMed:18256511, PubMed:18307993). Involved in the regulation of endosomal membrane tubulation and regulates the dynamics of SNX1 on the endosomal membrane; via association with WASHC2 may link the WASH complex to the retromer SNX-BAR subcomplex (

LOCALIZAÇÃO

Early endosomeEarly endosome membraneEndosome membrane

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Parkinson disease

A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
49.2 TPM
Artéria tibial
36.5 TPM
Útero
34.7 TPM
Aorta
33.5 TPM
Nervo tibial
32.8 TPM
OUTRAS DOENÇAS (1)
late-onset Parkinson disease
HGNC:30343UniProt:O75165
CHCHD2Coiled-coil-helix-coiled-coil-helix domain-containing protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor. Binds to the oxygen responsive element of COX4I2 and activates its transcription under hypoxia conditions (4% oxygen), as well as normoxia conditions (20% oxygen) (PubMed:23303788)

LOCALIZAÇÃO

NucleusMitochondrionMitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Parkinson disease 22

An autosomal dominant form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

OUTRAS DOENÇAS (1)
Parkinson disease 22, autosomal dominant
HGNC:HGNC:21645UniProt:Q9Y6H1
ATP13A2Polyamine-transporting ATPase 13A2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

ATPase which acts as a lysosomal polyamine exporter with high affinity for spermine (PubMed:31996848). Also stimulates cellular uptake of polyamines and protects against polyamine toxicity (PubMed:31996848). Plays a role in intracellular cation homeostasis and the maintenance of neuronal integrity (PubMed:22186024). Contributes to cellular zinc homeostasis (PubMed:24603074). Confers cellular protection against Mn(2+) and Zn(2+) toxicity and mitochondrial stress (PubMed:26134396). Required for pr

LOCALIZAÇÃO

Lysosome membraneLate endosome membraneEndosome, multivesicular body membraneCytoplasmic vesicle, autophagosome membrane

VIAS BIOLÓGICAS (1)
Ion transport by P-type ATPases
MECANISMO DE DOENÇA

Kufor-Rakeb syndrome

A rare form of autosomal recessive juvenile or early-onset, levodopa-responsive parkinsonism. In addition to typical parkinsonian signs, clinical manifestations of Kufor-Rakeb syndrome include behavioral problems, facial tremor, pyramidal tract dysfunction, supranuclear gaze palsy, and dementia.

OUTRAS DOENÇAS (3)
Kufor-Rakeb syndromeautosomal recessive spastic paraplegia type 78parkinsonism due to ATP13A2 deficiency
HGNC:30213UniProt:Q9NQ11
VPS13CIntermembrane lipid transfer protein VPS13CDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mediates the transfer of lipids between membranes at organelle contact sites (By similarity). Necessary for proper mitochondrial function and maintenance of mitochondrial transmembrane potential (PubMed:26942284). Involved in the regulation of PINK1/PRKN-mediated mitophagy in response to mitochondrial depolarization (PubMed:26942284)

LOCALIZAÇÃO

Mitochondrion outer membraneLipid dropletEndoplasmic reticulum membraneLysosome membraneLate endosome membrane

MECANISMO DE DOENÇA

Parkinson disease 23, autosomal recessive, early onset

An autosomal recessive, early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
32.4 TPM
Linfócitos
25.5 TPM
Pituitária
25.5 TPM
Ovário
24.2 TPM
Cerebelo
23.1 TPM
OUTRAS DOENÇAS (2)
autosomal recessive early-onset Parkinson disease 23young-onset Parkinson disease
HGNC:23594UniProt:Q709C8
FBXO7F-box only protein 7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferation, or maintenance of chromosome stability (PubMed:15145941, PubMed:34791250). Recognizes and ubiquitinates BIRC2 and the cell cycle regulator DLGAP5 (PubMed:15145941, PubMed:16510124, PubMed:22212761). Plays a role down

LOCALIZAÇÃO

CytoplasmNucleusMitochondrionCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Parkinson disease 15

A neurodegenerative disorder characterized by parkinsonian and pyramidal signs. Clinical manifestations include tremor, bradykinesia, rigidity, postural instability, spasticity, mainly in the lower limbs, and hyperreflexia.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
262.0 TPM
Testículo
184.1 TPM
Tireoide
184.1 TPM
Brain Spinal cord cervical c-1
122.6 TPM
Nervo tibial
110.3 TPM
OUTRAS DOENÇAS (1)
parkinsonian-pyramidal syndrome
HGNC:13586UniProt:Q9Y3I1
PLA2G685/88 kDa calcium-independent phospholipase A2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium-independent phospholipase involved in phospholipid remodeling with implications in cellular membrane homeostasis, mitochondrial integrity and signal transduction. Hydrolyzes the ester bond of the fatty acyl group attached at sn-1 or sn-2 position of phospholipids (phospholipase A1 and A2 activity respectively), producing lysophospholipids that are used in deacylation-reacylation cycles (PubMed:10092647, PubMed:10336645, PubMed:20886109, PubMed:9417066). Hydrolyzes both saturated and unsa

LOCALIZAÇÃO

CytoplasmCell membraneMitochondrionCell projection, pseudopodium

VIAS BIOLÓGICAS (4)
Acyl chain remodelling of PCAcyl chain remodelling of PERole of phospholipids in phagocytosisCOPI-independent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Neurodegeneration with brain iron accumulation 2B

A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. It is characterized by progressive extrapyramidal dysfunction leading to rigidity, dystonia, dysarthria and sensorimotor impairment.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
100.1 TPM
Testículo
71.7 TPM
Fallopian Tube
51.2 TPM
Cervix Endocervix
48.7 TPM
Ovário
43.2 TPM
OUTRAS DOENÇAS (3)
autosomal recessive Parkinson disease 14neurodegeneration with brain iron accumulation 2Aneurodegeneration with brain iron accumulation 2B
HGNC:9039UniProt:O60733
SYNJ1Synaptojanin-1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Phosphatase that acts on various phosphoinositides, including phosphatidylinositol 4-phosphate, phosphatidylinositol (4,5)-bisphosphate and phosphatidylinositol (3,4,5)-trisphosphate (PubMed:23804563, PubMed:27435091). Has a role in clathrin-mediated endocytosis (By similarity). Hydrolyzes PIP2 bound to actin regulatory proteins resulting in the rearrangement of actin filaments downstream of tyrosine kinase and ASH/GRB2 (By similarity)

LOCALIZAÇÃO

Cytoplasm, perinuclear region

VIAS BIOLÓGICAS (4)
Synthesis of PIPs at the plasma membraneClathrin-mediated endocytosisSynthesis of IP3 and IP4 in the cytosolSynthesis of IP2, IP, and Ins in the cytosol
MECANISMO DE DOENÇA

Parkinson disease 20, early-onset

An early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK20 is characterized by young adult-onset of parkinsonism. Additional features may include seizures, cognitive decline, abnormal eye movements, and dystonia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
38.4 TPM
Brain Frontal Cortex BA9
35.2 TPM
Cerebelo
33.2 TPM
Córtex cerebral
21.4 TPM
Testículo
18.7 TPM
OUTRAS DOENÇAS (5)
early-onset Parkinson disease 20developmental and epileptic encephalopathy, 53atypical juvenile parkinsonismundetermined early-onset epileptic encephalopathy
HGNC:11503UniProt:O43426
PRKNE3 ubiquitin-protein ligase parkinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins (PubMed:10888878, PubMed:10973942, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:15105460, PubMed:16135753, PubMed:21376232, PubMed:21532592, PubMed:22396657, PubMed:23620051, PubMed:23754282, PubMed:24660806, PubMed:24751536, PubMed:29311685, PubMed:32047033). Substrates include SYT11 and VDAC1 (PubMed:29311685, PubMed:32047033). Other substra

LOCALIZAÇÃO

Cytoplasm, cytosolNucleusEndoplasmic reticulumMitochondrionMitochondrion outer membraneCell projection, neuron projectionPostsynaptic densityPresynapse

VIAS BIOLÓGICAS (5)
AggrephagyPINK1-PRKN Mediated MitophagyAntigen processing: Ubiquitination & Proteasome degradationAmyloid fiber formationJosephin domain DUBs
MECANISMO DE DOENÇA

Parkinson disease

A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

OUTRAS DOENÇAS (4)
ovarian cancerautosomal recessive juvenile Parkinson disease 2lung canceryoung-onset Parkinson disease
HGNC:8607UniProt:O60260
PARK7Parkinson disease protein 7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Multifunctional protein with controversial molecular function which plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox-sensitive chaperone and protease (PubMed:12796482, PubMed:17015834, PubMed:18711745, PubMed:19229105, PubMed:20304780, PubMed:25416785, PubMed:26995087, PubMed:28993701). It is involved in neuroprotective mechanisms like the stabilization of NFE2L2 and PINK1 proteins, male fertility as a positive regulat

LOCALIZAÇÃO

Cell membraneCytoplasmNucleusMembrane raftMitochondrionEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
SUMOylation of transcription cofactors
MECANISMO DE DOENÇA

Parkinson disease 7

A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease).

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
303.7 TPM
Fibroblastos
302.9 TPM
Cérebro - Hemisfério cerebelar
277.7 TPM
Aorta
273.1 TPM
Nervo tibial
258.0 TPM
OUTRAS DOENÇAS (3)
autosomal recessive early-onset Parkinson disease 7amyotrophic lateral sclerosis-parkinsonism-dementia complexyoung-onset Parkinson disease
HGNC:16369UniProt:Q99497
PTPAReceptor-type tyrosine-protein phosphatase alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine protein phosphatase which is involved in integrin-mediated focal adhesion formation (By similarity). Following integrin engagement, specifically recruits BCAR3, BCAR1 and CRK to focal adhesions thereby promoting SRC-mediated phosphorylation of BRAC1 and the subsequent activation of PAK and small GTPase RAC1 and CDC42 (By similarity)

LOCALIZAÇÃO

Cell membraneCell junction, focal adhesion

VIAS BIOLÓGICAS (2)
RAF/MAP kinase cascadeNCAM signaling for neurite out-growth
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
133.6 TPM
Brain Frontal Cortex BA9
89.8 TPM
Córtex cerebral
87.8 TPM
Próstata
83.7 TPM
Cerebelo
83.2 TPM
OUTRAS DOENÇAS (1)
Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development
HGNC:HGNC:9308UniProt:P18433
PINK1Serine/threonine-protein kinase PINK1, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine/threonine-protein kinase which acts as a sensor of mitochondrial damage and protects against mitochondrial dysfunction during cellular stress (PubMed:40080546). It phosphorylates mitochondrial proteins to coordinate mitochondrial quality control mechanisms that remove and replace dysfunctional mitochondrial components (PubMed:14607334, PubMed:15087508, PubMed:18443288, PubMed:18957282, PubMed:19229105, PubMed:19966284, PubMed:20404107, PubMed:20547144, PubMed:20798600, PubMed:22396657, Pu

LOCALIZAÇÃO

Mitochondrion outer membraneMitochondrion inner membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
PINK1-PRKN Mediated MitophagyFOXO-mediated transcription of cell death genes
MECANISMO DE DOENÇA

Parkinson disease 6

An early-onset form of Parkinson disease, a neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep. PARK6 pathogenesis involves respiratory complex I deficiency causing mitochondrial depolarization and dysfunction. Inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
84.3 TPM
Brain Frontal Cortex BA9
68.5 TPM
Testículo
64.4 TPM
Glândula adrenal
61.7 TPM
Córtex cerebral
61.0 TPM
OUTRAS DOENÇAS (2)
autosomal recessive early-onset Parkinson disease 6young-onset Parkinson disease
HGNC:14581UniProt:Q9BXM7
SNCAAlpha-synucleinDisease-causing germline mutation(s) inModerado
FUNÇÃO

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release (PubMed:20798282, PubMed:26442590, PubMed:28288128, PubMed:30404828). Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed:28288128, PubMed:30404828). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enha

LOCALIZAÇÃO

CytoplasmMembraneNucleusSynapseSecretedCell projection, axon

VIAS BIOLÓGICAS (2)
PKR-mediated signalingAmyloid fiber formation
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
106.1 TPM
Brain Frontal Cortex BA9
106.0 TPM
Brain Anterior cingulate cortex BA24
75.0 TPM
Cerebelo
73.9 TPM
Nervo tibial
67.0 TPM
OUTRAS DOENÇAS (6)
autosomal dominant Parkinson disease 4autosomal dominant Parkinson disease 1Lewy body dementiayoung-onset Parkinson disease
HGNC:11138UniProt:P37840

Medicamentos e terapias

CARBIDOPAPhase 4

Mecanismo: DOPA decarboxylase inhibitor

AMANTADINE HYDROCHLORIDEPhase 4

Mecanismo: Glutamate [NMDA] receptor antagonist

LEVODOPAPhase 4

Mecanismo: Dopamine D3 receptor agonist

OPICAPONEPhase 4

Mecanismo: Catechol O-methyltransferase inhibitor

ROPINIROLE HYDROCHLORIDEPhase 4

Mecanismo: D2-like dopamine receptor agonist

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

147 variantes patogênicas registradas no ClinVar.

🧬 DNAJC6: GRCh37/hg19 1p31.3-22.3(chr1:61397219-85940743)x1 ()
🧬 DNAJC6: GRCh37/hg19 1p31.3-21.3(chr1:65412037-95735764)x1 ()
🧬 DNAJC6: NM_001256864.2(DNAJC6):c.661T>C (p.Cys221Arg) ()
🧬 DNAJC6: NM_001256864.2(DNAJC6):c.-4G>A ()
🧬 DNAJC6: NM_001256864.2(DNAJC6):c.1034T>C (p.Leu345Ser) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

79 vias biológicas associadas aos genes desta condição.

Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis Clathrin-mediated endocytosis Caspase-mediated cleavage of cytoskeletal proteins Activation of AMPK downstream of NMDARs PKR-mediated signaling RA biosynthesis pathway Ethanol oxidation HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome SIRT1 negatively regulates rRNA expression NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression RNA Polymerase II Pre-transcription Events Regulation of TP53 Activity through Phosphorylation RNA polymerase II transcribes snRNA genes RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Escape RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase I Transcription Termination RNA Polymerase III Abortive And Retractive Initiation RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter Estrogen-dependent gene expression Josephin domain DUBs FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes PODXL2 TPST1,2 transfer SO4(2-) from PAPS to PODXL2 Mitochondrial protein degradation Mitochondrial unfolded protein response (UPRmt) UCH proteinases Ribosome-associated quality control ISG15 antiviral mechanism L13a-mediated translational silencing of Ceruloplasmin expression mTORC1-mediated signalling Deadenylation of mRNA AUF1 (hnRNP D0) binds and destabilizes mRNA Translation initiation complex formation Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit Regulation of expression of SLITs and ROBOs Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) M-decay: degradation of maternal mRNAs by maternally stored factors Z-decay: degradation of maternal mRNAs by zygotically expressed factors Dengue Virus Genome Translation and Replication Association of TriC/CCT with target proteins during biosynthesis Glycosphingolipid catabolism PTK6 promotes HIF1A stabilization WNT ligand biogenesis and trafficking Neutrophil degranulation Mitochondrial protein import Ion transport by P-type ATPases Neddylation Antigen processing: Ubiquitination & Proteasome degradation Acyl chain remodelling of PC Acyl chain remodeling of CL Acyl chain remodelling of PE Role of phospholipids in phagocytosis COPI-independent Golgi-to-ER retrograde traffic Synthesis of PIPs at the plasma membrane Synthesis of IP2, IP, and Ins in the cytosol Synthesis of IP3 and IP4 in the cytosol PINK1-PRKN Mediated Mitophagy Regulation of necroptotic cell death Aggrephagy Amyloid fiber formation SUMOylation of transcription cofactors Chaperone Mediated Autophagy Late endosomal microautophagy NCAM signaling for neurite out-growth RAF/MAP kinase cascade FOXO-mediated transcription of cell death genes

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado5
Medicamentos catalogadosEnsaios clínicos· 5 medicamentos · 0 ensaios
✓ Aprovados — podem ser usados hoje
CARBIDOPAAMANTADINE HYDROCHLORIDELEVODOPAOPICAPONEROPINIROLE HYDROCHLORIDE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — NÃO RARA NA EUROPA: Doença de Parkinson

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Observacional
Timeline de publicações
0 papers (10 anos)
#1

Familial risk of Wolff-Parkinson-White syndrome: a nationwide family study in Sweden.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025 Oct 31

Wolff-Parkinson-White (WPW) syndrome is a rare cardiac disorder that predisposes to supraventricular arrhythmias. Prognosis is usually benign, yet there is an increased lifetime risk of sudden death. While typically sporadic, familial clustering has been reported. This study aimed to assess the risk of WPW, arrhythmias, and mortality among siblings of individuals with WPW. This population-based sibling cohort included 5 338 434 individuals born in Sweden (1932-2018), with 3172 WPW cases identified from the Swedish National Patient Registers. Familial risks among siblings were assessed using incidence rate ratios (IRRs) and adjusted subdistributional hazard ratios (SHRs). Sensitivity analyses excluded syndromic WPW and cases without electrophysiologic procedural confirmation. Although familial occurrence of WPW was exceedingly rare with only 14 of 3172 cases (0.4%; ≈0.0003% of the total population), siblings of affected individuals showed a significantly higher rate of WPW diagnosis (0.121 vs. 0.032 per 1000 person-years; IRR 3.83; 95% CI 2.27-6.46; P < 0.001) translating to an almost four-fold higher adjusted risk (SHR 3.79; 95% CI 1.81-7.97; P < 0.001). Risks of atrial fibrillation (SHR 1.19; 95% CI 1.05-1.35; P < 0.01) and ventricular arrhythmias (SHR 1.84; 95% CI 1.45-2.35; P < 0.001) were also higher, whereas all-cause mortality was comparable irrespective of sibling history (HR 1.01; 95% CI 0.92-1.11; P = 0.88). WPW features familial aggregation and increased arrhythmic risk among siblings of affected individuals despite its extremely low absolute frequency in the general population. The evidence of a measurable hereditary component within an otherwise sporadic, non-syndromic condition points to a genetic contribution driven by complex inheritance patterns.

#2

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)2025 Oct 18

Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.

#3

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)2025 Oct 18

For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant). Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors-eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic-the complex interaction of multiple health risks, social determinants, and systemic challenges-will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity. Gates Foundation and Bloomberg Philanthropies.

#4

Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019.

Nature communications2025 May 07

Chronic care manages long-term, progressive conditions, while acute care addresses short-term conditions. Chronic conditions increasingly strain health systems, which are often unprepared for these demands. This study examines the burden of conditions requiring acute versus chronic care, including sequelae. Conditions and sequelae from the Global Burden of Diseases Study 2019 were classified into acute or chronic care categories. Data were analysed by age, sex, and socio-demographic index, presenting total numbers and contributions to burden metrics such as Disability-Adjusted Life Years (DALYs), Years Lived with Disability (YLD), and Years of Life Lost (YLL). Approximately 68% of DALYs were attributed to chronic care, while 27% were due to acute care. Chronic care needs increased with age, representing 86% of YLDs and 71% of YLLs, and accounting for 93% of YLDs from sequelae. These findings highlight that chronic care needs far exceed acute care needs globally, necessitating health systems to adapt accordingly.

#5

The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease.

European journal of neurology2025 Feb

The p.A53T variant in the SNCA gene was considered, until recently, to be the only SNCA variant causing familial Parkinson's disease (PD) in the Greek population. We identified a novel heterozygous p.A30G (c.89 C>G) SNCA pathogenic variant in five affected individuals of three Greek families, leading to autosomal dominant PD. This study aims to further explore the presence and phenotypic expression of this variant in the Greek PD population. Restriction fragment length polymorphism (RFLPs) was used for genotyping of 664 Greek PD cases. Detailed clinical information was obtained for the carriers and p.A30G-positive samples underwent haplotype analysis. We identified 10 additional p.A30G-positive PD patients (1.5%), of whom 4 were sporadic cases (0.9%). They manifested typical Parkinsonian motor dysfunction, with a mean age of onset of 51.7 years (range: 33-62) and a broad spectrum of non-motor symptoms. The absence of affected first degree relatives in four out of ten index cases, and the presence of a phenocopy in an additional family, suggest that the p.A30G variant manifests reduced penetrance. The common haplotype among the p.A30G carriers confirmed a founder effect. Furthermore, two asymptomatic carriers were identified, with possible premotor manifestations. These findings underscore that the p.A30G SNCA pathogenic variant represents an important, albeit rare, cause of genetic PD in the Greek population. This is the first time in which a genetic synucleinopathy, with a variant in the SNCA gene, is clearly linked to an appreciable frequency of sporadic PD in a particular population.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 81

2025

The genetic architecture of Parkinson's disease on the Island of Crete.

NPJ Parkinson's disease
2025

Documented End-of-Life Preferences of People With Parkinson's Disease or Parkinsonism Across Europe.

Movement disorders clinical practice
2025

Familial risk of Wolff-Parkinson-White syndrome: a nationwide family study in Sweden.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2025

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2025

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2025

Vortioxetine in the routine management of major depressive disorder: an analysis of European automated healthcare databases.

Current medical research and opinion
2025

Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019.

Nature communications
2025

Exome sequencing of a Portuguese cohort of early-onset Alzheimer's disease implicates the X-linked lysosomal gene GLA.

Scientific reports
2025

Comprehensive analysis of SLC17A5 variants in large European cohorts reveals no association with Parkinson's disease risk.

Parkinsonism &amp; related disorders
2025

The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease.

European journal of neurology
2025

Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.

Journal of neurology
2025

A Population-Wide Exploration of the THAP11 CAG Repeat Size and Structure in the 100,000 Genomes Project and UK Biobank.

Movement disorders : official journal of the Movement Disorder Society
2024

Reliable change indices for the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson's disease patients.

BMC neurology
2024

Study protocol of the HessenKohorte2042: a prospective, longitudinal cohort study characterising quality of life in people with Parkinson's disease and their caregivers using a bio-psycho-social approach.

BMJ open
2025

Genetic mutations in Parkinson's disease: screening of a selected population from North-Eastern Italy.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Association of Autoimmune Diseases with the Risk of Parkinson's Disease.

Neuroepidemiology
2024

Air pollution exposure and mortality from neurodegenerative diseases in the Netherlands: A population-based cohort study.

Environmental research
2024

Extended genome-wide association study employing the African genome resources panel identifies novel susceptibility loci for Alzheimer's disease in individuals of African ancestry.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2024

Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells.

Stem cells (Dayton, Ohio)
2024

MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study.

The Lancet. Neurology
2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

Lancet (London, England)
2024

Psychometrics and diagnostics of the Italian version of the Alternate Verbal Fluency Battery (AVFB) in non-demented Parkinson's disease patients.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2024

Validation of the Italian version of the Parkinson's Disease- Cognitive Functional Rating Scale.

Journal of neural transmission (Vienna, Austria : 1996)
2024

Gene therapy for neurotransmitter-related disorders.

Journal of inherited metabolic disease
2023

Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches.

Cells
2023

Association of Rare Variants in ARSA with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society
2023

Management of rare movement diseases in different world regions.

Parkinsonism &amp; related disorders
2024

Myasthenia Gravis crossing Parkinson's disease: a 20 year study from single Italian center.

The International journal of neuroscience
2022

An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders: The Case for N-of-1 Trials in Holmes Tremor.

Frontiers in human neuroscience
2022

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.

JAMA network open
2022

Development of a patient journey map for people living with cervical dystonia.

Orphanet journal of rare diseases
2022

Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study.

The Lancet. Neurology
2021

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

Frontiers in neurology
2022

RIC3 variants are not associated with Parkinson's disease in large European, Latin American, or East Asian cohorts.

Neurobiology of aging
2021

Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease.

Neurobiology of aging
2021

Screening of LRP10 mutations in Parkinson's disease patients from Italy.

Parkinsonism &amp; related disorders
2021

Common and rare variants in HFE are not associated with Parkinson's disease in Europeans.

Neurobiology of aging
2021

Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases.

European journal of human genetics : EJHG
2021

Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.

Science translational medicine
2021

A glimpse of the genetics of young-onset Parkinson's disease in Central Asia.

Molecular genetics &amp; genomic medicine
2021

Quality of life in isolated dystonia: non-motor manifestations matter.

Journal of neurology, neurosurgery, and psychiatry
2021

Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers.

Liver international : official journal of the International Association for the Study of the Liver
2021

Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.

Movement disorders : official journal of the Movement Disorder Society
2021

Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Molecular therapy : the journal of the American Society of Gene Therapy
2021

A population scale analysis of rare SNCA variation in the UK Biobank.

Neurobiology of disease
2021

Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans.

Neurobiology of aging
2020

English version of the self-administered Fabry Pain Questionnaire for adult patients.

Orphanet journal of rare diseases
2020

LifeTime and improving European healthcare through cell-based interceptive medicine.

Nature
2020

A genetic analysis of a Spanish population with early onset Parkinson's disease.

PloS one
2020

Wilson's Disease in Finland: A Nationwide Population-Based Study.

Movement disorders : official journal of the Movement Disorder Society
2020

Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study.

Journal of neurology, neurosurgery, and psychiatry
2020

Is Parkinson's Disease a Very Rare Pathology in Centenarians? A Clinical Study in a Cohort of Subjects.

Journal of Alzheimer's disease : JAD
2020

Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study.

Neuroepidemiology
2019

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.

Parkinsonism &amp; related disorders
2019

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.

The Lancet. Neurology
2019

Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study.

Parkinsonism &amp; related disorders
2019

LRP10 variants in Parkinson's disease and dementia with Lewy bodies in the South-West of the Netherlands.

Parkinsonism &amp; related disorders
2018

Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society
2018

Nonataxia symptoms in Friedreich Ataxia: Report from the Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS).

Neurology
2018

Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population.

Neurobiology of aging
2018

LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.

The Lancet. Neurology
2018

Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis.

Neurobiology of aging
2018

Prevalence of functional (psychogenic) parkinsonism in two Swiss movement disorders clinics and review of the literature.

Journal of the neurological sciences
2017

Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.

Journal of Parkinson's disease
2017

Mutations in TMEM230 are rare in autosomal dominant Parkinson's disease.

Parkinsonism &amp; related disorders
2017

Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients.

Neurobiology of aging
2016

Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort.

Neuroscience letters
2016

Genome-wide assessment of Parkinson's disease in a Southern Spanish population.

Neurobiology of aging
2016

Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.

Neurobiology of aging
2016

Phenotype and natural history of inherited neuropathies caused by HSJ1 c.352+1G>A mutation.

Journal of neurology, neurosurgery, and psychiatry
2016

Linking rare and common disease: mapping clinical disease-phenotypes to ontologies in therapeutic target validation.

Journal of biomedical semantics
2016

Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes.

European journal of neurology
2016

An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson's disease.

Neuroscience letters
2016

Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants.

Neurobiology of aging
2016

MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.

Journal of Alzheimer's disease : JAD
2016

Convergent Genetic and Expression Datasets Highlight TREM2 in Parkinson's Disease Susceptibility.

Molecular neurobiology
2015

Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family.

Parkinsonism &amp; related disorders
2016

Motor complications in an incident Parkinson's disease cohort.

European journal of neurology
2015

The MC1R melanoma risk variant p.R160W is associated with Parkinson disease.

Annals of neurology
2015

TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study.

Parkinsonism &amp; related disorders
2015

Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.

The Lancet. Neurology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para NÃO RARA NA EUROPA: Doença de Parkinson.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para NÃO RARA NA EUROPA: Doença de Parkinson

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Familial risk of Wolff-Parkinson-White syndrome: a nationwide family study in Sweden.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology· 2025· PMID 41206697mais citado
  2. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet (London, England)· 2025· PMID 41092928mais citado
  3. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet (London, England)· 2025· PMID 41092926mais citado
  4. Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019.
    Nature communications· 2025· PMID 40335470mais citado
  5. The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease.
    European journal of neurology· 2025· PMID 39878395mais citado
  6. Postural control in Parkinson's disease.
    Braz J Otorhinolaryngol· 2014· PMID 25457071recente
  7. Dysphagia progression and swallowing management in Parkinson's disease: an observational study.
    Braz J Otorhinolaryngol· 2015· PMID 25450106recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:319705(Orphanet)
  2. MONDO:0005180(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

NÃO RARA NA EUROPA: Doença de Parkinson
Compêndio · Raras BR

NÃO RARA NA EUROPA: Doença de Parkinson

ORPHA:319705 · MONDO:0005180
CID-10
G20 · Doença de Parkinson
Medicamentos
5 registrados
MedGen
Wikipedia
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades